Trial reportHeart (British Cardiac Society)2017
Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.
Trial report in Heart (British Cardiac Society), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00855465 (Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521), which is not on this map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Pooled it
- Meta-Analysis of Real-World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2025Pooled it
- Pooled it
- Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis.Clinical cardiology · 2019Pooled it
- The Therapeutic Efficacy of Drugs Targeting the NO-sGC-cGMP Pathway in Treatment of Patients With Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review.Pulmonary circulation · 2026Review
- Sex-Specific Differences in Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.Journal of clinical medicine · 2025Article
- The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Role of Surgical and Medical Management of Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review.Cureus · 2024Review
- Clinical-radiological-pathological correlation in chronic thromboembolic pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2023Article
- Article
- Impact of residual pulmonary hypertension on long-term outcomes after pulmonary endarterectomy in the modern era.Pulmonary circulation · 2023Article
- Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- A Comprehensive Assessment of Right Ventricular Function in Chronic Thromboembolic Pulmonary Hypertension.Journal of clinical medicine · 2022Review
- Recognizing pulmonary hypertension following pulmonary thromboendarterectomy: A practical guide for clinicians.Pulmonary circulation · 2022Review
- Riociguat: Clinical research and evolving role in therapy.British journal of clinical pharmacology · 2021Review
- Chronic Thromboembolic Pulmonary Hypertension Medical Management.Methodist DeBakey cardiovascular journal · 2021Article
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.Clinical pharmacokinetics · 2018Review
- The changing landscape of chronic thromboembolic pulmonary hypertension management.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies.Pulmonary circulationArticle
- Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension.Pulmonary circulationReview
Corrections and comments
- Commented on by
Authors and funding
14 authors at 12 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1 study.
methodsPatients with inoperable or persistent/recurrent CTEPH (n=261; mean± SD age 59±14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or placebo. Haemodynamic parameters were assessed at baseline and week 16.
resultsRiociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: -285 dyn s/cm
conclusionsRiociguat improved haemodynamics in patients with inoperable CTEPH or persistent/recurrent CTEPH. TRIAL REGISTRATION NUMBER: NCT00855465.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.